Efgartigimod is entering a Phase 3 clinical trial after data from a proof-of-concept Phase 2 trial showed it outperformed a placebo at easing symptoms and signs of primary Sjögren’s disease, the treatment’s developer said. Argenx shared the data at the European Congress of Rheumatology (EULAR) 2025, held June…
News
Newborns of mothers with primary Sjögren’s disease may be at a higher risk of developing heart conditions. That’s according to a study in China, which also found this increased risk was significantly associated with higher maternal disease activity. “Maternal [primary Sjögren’s], especially with high disease activity, elevates the risk…
A study found significant associations between eye surface changes and alterations in immune activity throughout the body in people with primary Sjögren’s disease. “These results provide new insights into the relationship between ocular surface and systemic [whole body] status in patients with [primary Sjögren’s disease],” the researchers wrote. The study,…
People with Sjögren’s disease are at higher risk of developing non-Hodgkin lymphoma (NHL), a type of blood cancer, as well as other malignancies, a study reports. Researchers also identified several risk factors associated with cancer development in Sjögren’s patients, noting that nearly a quarter of deaths seen among…
Using stem cell eye drops — ones containing mesenchymal stem cells, or MSCs, which can give rise to other cell types — was shown to ease the signs and symptoms of refractory, or hard-to-treat, dry eye disease in adults with and without Sjögren’s disease, according to new data from…
Cullinan Therapeutics is planning the launch of a clinical trial in the U.S. to test its treatment candidate CLN-978 in people with Sjögren’s disease. The study will be open to Sjögren’s patients whose disease is active and moderate to severe, and who are positive for anti-SSA/Ro antibodies and/or…
Immunovant is planning to launch a potentially registrational clinical trial this summer to test its treatment candidate IMVT-1402 in people with Sjögren’s disease. The company said that its investigational new drug application — a formal request to the U.S. Food and Drug Administration (FDA) seeking permission to start…
Men with Sjögren’s disease show more early signs of lung and heart dysfunction than women and may be at an increased risk of developing pulmonary hypertension, a cardiovascular complication of Sjögren’s, a study reports. “As male patients demonstrated a greater predisposition to developing [pulmonary hypertension] … regular echocardiographic…
A naturally occurring molecule that has the ability to regulate gene activity may represent a promising therapeutic target for Sjögren’s disease and other autoimmune conditions, according to a study. Mimicking the activity of the molecule, miR-216a-3p, eased inflammation and scarring in a rat model of the disease. Its therapeutic…
More severe salivary gland damage and lymph node enlargement detected by ultrasound examination are associated with higher disease activity in primary Sjögren’s disease, a study in South Korea reports. Also, researchers found that more severe salivary gland damage was tied to a higher prevalence of laboratory risk factors for…
Recent Posts
- Global trial of telitacicept for Sjögren’s doses first patient ‘within weeks’
- Patients, advocates working this month to raise awareness of Sjögren’s
- Biotech, US university partner on new ways to speed Sjögren’s diagnosis
- New study links alternative splicing patterns to Sjögren’s severity
- Initial data from trial testing CLN-978 in Sjögren’s expected this year
- Sjögren’s disease may increase risk of certain digestive cancers: Korean study
- Sjögren’s patients face ‘invisible’ symptoms, lack of understanding
- Sjögren’s protein score may help measure salivary gland inflammation
- AI tools find 12 biomarkers that may speed a Sjögren’s diagnosis
- Investment funds development of ‘Goldilocks’ treatment for dry eyes